FAST is proud to announce the publication of the ATMP-NL report, an important milestone in further strengthening the Dutch ATMP ecosystem. The report was produced in collaboration with a broad group of stakeholders, with support from Inovigate, and marks the next step in joining forces within the field of Advanced Therapy Medicinal Products (ATMPs).

Over the past year, FAST has brought together stakeholders from the ATMP-NL initiative, ranging from patient representatives, academic institutions, and healthcare professionals to industry, regulatory authorities, and public partners. During a series of roundtable discussions, the main bottlenecks, opportunities, and shared priorities in the development and implementation of ATMPs in the Netherlands were identified. The report brings together these insights, forming a common basis for coordinated follow-up steps.

View the report here

We would like to thank all participants for their active involvement, openness, and valuable contributions throughout this process. The collective input from the field has been essential for both the analysis and the direction going forward.

The next phase of ATMP-NL will focus on collective action. The ATMP-NL action groups will be launched in the first quarter of this year. Their goal is to translate the identified priorities into concrete and achievable initiatives that contribute to the sustainable development and accessibility of ATMPs in the Netherlands.

With this next step, FAST, together with its partners, is underlining its ambition to strengthen structural cooperation and bring innovation in advanced therapies to patients more quickly in a sustainable manner. Follow the activities of ATMP-NL here and sign up for the newsletter.